Thromboembolic events associated with antiangiogenic monoclonal antibodies: a disproportionality analysis from FDA adverse event reporting system (FAERS) database. [PDF]
Thromb JZhou H, Su Y, Song J, Zhen L.
europepmc +1 more source
Beyond LEAP-015: the ongoing challenge of vascular endothelial growth factor inhibition in gastric cancer. [PDF]
J Gastrointest OncolAbidoye O, Sonbol MB.
europepmc +1 more source
Comments on "Prior Immunotherapy Enhances Survival Outcomes of Third-Line Apatinib Treatment in Advanced Gastric Cancer: A Retrospective Cohort Study". [PDF]
Int J CancerXu H, Lu J.
europepmc +1 more source
Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung Cancer. [PDF]
Case Rep Oncol MedYokota H +8 more
europepmc +1 more source
Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review. [PDF]
Curr OncolLoizidis S +6 more
europepmc +1 more source
Perforated Gastric Cancer: Epidemiology, Diagnosis, and Surgical Management Strategies. [PDF]
J Clin MedJeong SH, Oh SJ, Seo KW, Min JS.
europepmc +1 more source
Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study. [PDF]
J Gastrointest OncolBoku N.
europepmc +1 more source
First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma. [PDF]
Ther Adv Med OncolMarchesi S +11 more
europepmc +1 more source
Regorafenib in refractory gastric cancer: modest median, meaningful milestone. [PDF]
J Gastrointest OncolNarita Y, Muro K.
europepmc +1 more source